<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Soureas, K.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, M. A.</style></author><author><style face="normal" font="default" size="100%">Malandrakis, P.</style></author><author><style face="normal" font="default" size="100%">Papanota, A. M.</style></author><author><style face="normal" font="default" size="100%">Adamopoulos, P.G.</style></author><author><style face="normal" font="default" size="100%">Ntanasis-Stathopoulos, I.</style></author><author><style face="normal" font="default" size="100%">Liacos, C. I.</style></author><author><style face="normal" font="default" size="100%">Gavriatopoulou, M.</style></author><author><style face="normal" font="default" size="100%">Sideris, D. C.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Scorilas, A.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Avgeris, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRF(HisGTG) results in patients' poor treatment outcome</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Haematology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Multiple Myeloma/genetics/mortality/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">CD138+ plasma cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">haematological cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">internal tRFs</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Mitochondria/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">mitochondrial tRFs</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular markers</style></keyword><keyword><style  face="normal" font="default" size="100%">non-coding RNAs</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Transfer/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA-Seq</style></keyword><keyword><style  face="normal" font="default" size="100%">Small RNA-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">tRF-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">tRFs</style></keyword><keyword><style  face="normal" font="default" size="100%">tRNA-derived fragments</style></keyword><keyword><style  face="normal" font="default" size="100%">tRNA-derived small RNA fragments</style></keyword><keyword><style  face="normal" font="default" size="100%">tsRNAs</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">204</style></volume><pages><style face="normal" font="default" size="100%">1790-1800</style></pages><isbn><style face="normal" font="default" size="100%">1365-2141 (Electronic)0007-1048 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Despite the substantial progress in multiple myeloma (MM) therapy nowadays, treatment resistance and disease relapse remain major clinical hindrances. Herein, we have investigated tRNA-derived fragment (tRF) profiles in MM and precursor stages (smoldering MM/sMM; monoclonal gammopathy of undetermined significance/MGUS), aiming to unveil potential MM-related tRFs in ameliorating MM prognosis and risk stratification. Small RNA-seq was performed to profile tRFs in bone marrow CD138(+) plasma cells, revealing the significant deregulation of the mitochondrial internal tRF(HisGTG) (mt-i-tRF(HisGTG)) in MM versus sMM/MGUS. The screening cohort of the study consisted of 147 MM patients, and mt-i-tRF(HisGTG) levels were quantified by RT-qPCR. Disease progression was assessed as clinical end-point for survival analysis, while internal validation was performed by bootstrap and decision curve analyses. Screening cohort analysis highlighted the potent association of reduced mt-i-tRF(HisGTG) levels with patients' bone disease (p = 0.010), osteolysis (p = 0.023) and with significantly higher risk for short-term disease progression following first-line chemotherapy, independently of patients' clinical data (HR = 1.954; p = 0.036). Additionally, mt-i-tRF(HisGTG)-fitted multivariate models led to superior risk stratification of MM patients' treatment outcome and prognosis compared to disease-established markers. Notably, our study highlighted mt-i-tRF(HisGTG) loss as a powerful independent indicator of post-treatment progression of MM patients, leading to superior risk stratification of patients' treatment outcome.</style></abstract><accession-num><style face="normal" font="default" size="100%">38414235</style></accession-num><notes><style face="normal" font="default" size="100%">Soureas, KonstantinosPapadimitriou, Maria-AlexandraMalandrakis, PanagiotisPapanota, Aristea-MariaAdamopoulos, Panagiotis GNtanasis-Stathopoulos, IoannisLiacos, Christine-IvyGavriatopoulou, MariaSideris, Diamantis CKastritis, EfstathiosDimopoulos, Meletios-AthanasiosScorilas, AndreasTerpos, EvangelosAvgeris, Margaritiseng101097094/European Union/England2024/02/28 06:45Br J Haematol. 2024 May;204(5):1790-1800. doi: 10.1111/bjh.19332. Epub 2024 Feb 27.</style></notes><auth-address><style face="normal" font="default" size="100%">Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece.Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, &quot;P. &amp; A. Kyriakou&quot; Children's Hospital, Athens, Greece.Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.</style></auth-address></record></records></xml>